IQVIA (IQV) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of IQVIA (NYSE: IQV) in the last few weeks:

• 2/18/2025 – IQVIA had its price target lowered by analysts at JPMorgan Chase & Co. from $240.00 to $232.00. They now have an “overweight” rating on the stock.
• 2/11/2025 – IQVIA had its price target raised by analysts at Morgan Stanley from $245.00 to $250.00. They now have an “overweight” rating on the stock.
• 2/10/2025 – IQVIA had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $270.00 price target on the stock.
• 2/10/2025 – IQVIA had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $263.00 price target on the stock, up previously from $261.00.
• 2/7/2025 – IQVIA had its price target lowered by analysts at UBS Group AG from $260.00 to $255.00. They now have a “buy” rating on the stock.
• 2/7/2025 – IQVIA had its price target lowered by analysts at Stifel Nicolaus from $273.00 to $261.00. They now have a “buy” rating on the stock.
• 2/3/2025 – IQVIA had its price target lowered by analysts at Barclays PLC from $255.00 to $235.00. They now have an “overweight” rating on the stock.
• 2/3/2025 – IQVIA was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
• 1/21/2025 – IQVIA had its price target lowered by analysts at Robert W. Baird from $212.00 to $210.00. They now have a “neutral” rating on the stock.

IQVIA Trading Up 1.9 %

Shares of NYSE:IQV traded up $3.67 during midday trading on Monday, hitting $194.71. 1,857,069 shares of the stock were exchanged, compared to its average volume of 1,419,882. The business’s 50-day moving average price is $199.57 and its 200 day moving average price is $216.25. The stock has a market capitalization of $34.29 billion, a price-to-earnings ratio of 25.96, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In other news, Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Private Trust Co. NA grew its stake in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares during the period. Clear Harbor Asset Management LLC increased its stake in IQVIA by 1.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its stake in shares of IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares in the last quarter. Howard Capital Management Inc. increased its position in shares of IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares in the last quarter. Finally, Fortitude Family Office LLC raised its holdings in shares of IQVIA by 2.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after acquiring an additional 56 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.